Read about the latest developments in the world of lung cancer. You'll find articles from the last 24 months.

June 2024

:
Nivolumab/Ipilimumab/Chemotherapy Combo Achieves Long-Term OS in NSCLC
(Targeted Oncology)
:
New SOC Consolidation Durvalumab Set in LS-SCLC
(Targeted Oncology)
:
Osimertinib Shows Potential to Alter SOC in Advanced EGFR+ NSCLC
(Targeted Oncology)

May 2024

:
CROWN Trial of Lorlatinib Offers Durable PFS in ALK+ Lung Cancer
(Targeted Oncology)
:
FDA grants accelerated approval to tarlatamab-dlle for extensive stage small ce…
(US Food and Drug Administration)

April 2024

:
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lu…
(US Food and Drug Administration)
:
Colorless, odorless gas likely linked to alarming rise in non-smoking lung canc…
(American Association for the Advancement of Science)
:
Optimizing Biomarker Testing in Early-Stage Disease for Patients With NSCLC
(Targeted Oncology)
:
Neoadjuvant Use of ICB in NSCLC Gains Favor
(Targeted Oncology)

March 2024

:
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell…
(US Food and Drug Administration)

February 2024

:
FDA Oks Osimertinib Plus Chemo in EGFR-Mutant Lung Cancer
(Targeted Oncology)
:
FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alte…
(OncLive)

November 2023

:
FDA approves repotrectinib for ROS1-positive non-small cell lung cancer
(US Food and Drug Administration)

October 2023

:
FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell …
(US Food and Drug Administration)
:
FDA approves encorafenib with binimetinib for metastatic non-small cell lung ca…
(US Food and Drug Administration)

April 2023

:
AACR: Lung cancer outcomes significantly improved with immunotherapy-based trea…
(AAAS)

February 2023

:
First-Line Combination Immunotherapy plus Chemotherapy in mNSCLC
(Targeted Oncology)
:
Toripalimab Plus Platinum Doublet Chemotherapy Prolongs EFS in Resectable NSCLC
(Targeted Oncology)

January 2023

:
FDA Approves Adjuvant Pembrolizumab for Stage IB-IIIA NSCLC
(Targeted Oncology)
:
Immunotherapy, Targeted Therapy Enter Localized Setting in Non–Small Cell Lung …
(Targeted Oncology)